Stereochemistry | ACHIRAL |
Molecular Formula | C16H20ClN3 |
Molecular Weight | 289.803 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCN(CC1=CC=C(Cl)C=C1)C2=CC=CC=N2
InChI
InChIKey=ICKFFNBDFNZJSX-UHFFFAOYSA-N
InChI=1S/C16H20ClN3/c1-19(2)11-12-20(16-5-3-4-10-18-16)13-14-6-8-15(17)9-7-14/h3-10H,11-13H2,1-2H3
Molecular Formula | C16H20ClN3 |
Molecular Weight | 289.803 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Chloropyramine is an antagonist of H1 histamine receptors. It is indicated for the treatment of various forms of allergic reactions. Chloropyramine is a drug capable of (1) inhibiting the biochemical function of VEGFR-3 and FAK, (2) inhibiting proliferation of a diverse set of cancer cell types in vitro, and (3) reducing tumor growth in vivo.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Composition:
One ampoule of 2 ml contains 20 mg chloropyramine hydrochloride (10 mg/ml).
One coated tablet contains 25 mg chloropyramine hydrochloride.
1 g of ointment (1%) contains 10 mg chloropyramine hydrochloride.
1 g of cream (1%) contains 10 mg chloropyramine hydrochloride.
Dosage and administration:
Parenteral administration: in severe allergic reactions 1-2 ampoules intramuscularly or intravenously.
Oral administration: adults - 25 mg (1 tabl.) 3-4 times daily (up to 150 mg, if necessary); children over 5 years: 1 tablet, 2-3 times daily.
External application: affected area should be treated once or several times a day by applying a thin layer of ointment or cream.
Route of Administration:
Other
SKN-AS and SK-N-BE(2) neuroblastoma cells were treated with varying concentrations of chloropyramine hydrochloride (C4) for 24 h and cellular viability was measured. Both cell lines demonstrated a decrease in survival that was signifi-cant at 100 μM concentration. The calculated LC50 for C4 was similar in the two cell lines at 170 μM in the SK-N-AS cell line and 144 mM in the SK-N-BE(2) cell line.